|Bid||69.86 x 800|
|Ask||69.89 x 200|
|Day's Range||68.44 - 70.57|
|52 Week Range||64.27 - 89.54|
|Beta (3Y Monthly)||1.39|
|PE Ratio (TTM)||57.90|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||2.28 (3.17%)|
|1y Target Est||86.15|
With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.
In November 2018, of the total ten analysts covering Nektar Therapeutics (NKTR), eight analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Nektar Therapeutics stock is 1.8 with a target price of $88.5, implying an upside potential of 160.1% over Nektar Therapeutics’ trading price of $34.03 on November 10.
Gilead Sciences, Inc. (GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC). PSC is a rare, chronic condition that causes the network of ducts that drain bile from the liver to become inflamed and scarred over time. Progressive damage to the bile ducts in patients with PSC can lead to cirrhosis, liver failure, and cholangiocarcinoma (cancer of the bile ducts).
– Data Demonstrate Sofosbuvir-Based Regimens Achieve High Cure Rates in Hepatitis C Patient Populations with Unmet Need –
Gilead Sciences, Inc. (GILD) today announced new data from the company’s clinical development program for advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Data presented support the ongoing development of the company’s investigational compounds, evaluate the utility of noninvasive tests for the identification of patients with advanced fibrosis, and demonstrate the significant burden of disease in affected patients. In this study, 140 NASH patients were treated with GS-9674 100 mg, GS-9674 30 mg or placebo orally once daily for 24 weeks.
Gilead Sciences Inc (NASDAQ:GILD), a large-cap worth US$91.0b, comes to mind for investors seeking a strong and reliable stock investment. Market participants who are conscious of risk tend to search Read More...
In November, among the 28 analysts covering Gilead Sciences (GILD), six recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold.” The mean rating for Gilead Sciences stock is 2.21 with a target price of $86.15, which implies an upside potential of 22.5% over Gilead Sciences’ closing price of $70.31 on November 1.
Gilead Sciences’ (GILD) total HIV sales got a boost from the US market. The HIV product sales in the United States increased from $2.52 billion in the third quarter of 2017 to $3.0 billion in the third quarter. The HIV product sales in Europe decreased from $656.0 million in the third quarter of 2017 to $584.0 million in the third quarter. The sales in other international markets decreased from $156.0 million in the third quarter of 2017 to $138.0 million in the third quarter. Gilead Sciences’ Biktarvy generated US sales of $375. ...
Gilead Sciences’ (GILD) cost of goods sold increased marginally from $1.03 billion in the third quarter of 2017 to $1.09 billion in the third quarter.
Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter. The company’s income tax provision also decreased from $959.0 million in the third quarter of 2017 to $565.0 million in the third quarter.
For Gilead Sciences’ (GILD) Biktarvy, declining revenues and stock price movements have kept investors interested in the stock. In this series, we’ll explore Gilead Sciences’ financials, the performance of the company’s geographic segments, analysts’ recommendations for the stock, and the company’s valuation metrics.
bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.
Jim Cramer issues a warning to investors about the pharmaceutical sector, which includes high-profile stocks like Allergan and Gilead.
Merck & Co.’s (MRK) Zepatier reported revenues of $104 million in the third quarter compared to $468 million in the third quarter of 2017, reflecting a ~78% YoY (year-over-year) decline and an 8% sequential decline.
-- Data Reinforce Breadth of Cell Therapy Portfolio and Commitment to Continued Innovation for People with Advanced Cancers --
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / U.S. equities rose on Wednesday as a number of high profile companies reported upbeat corporate earnings that helped boost investor confidence. The Dow Jones ...
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
Gilead Sciences, Inc. (GILD) and Tango Therapeutics, Inc., a company focused on the discovery and development of novel cancer therapies, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have options to worldwide rights on up to five targets emerging from Tango’s proprietary functional genomics-based discovery platform.
NEW YORK, Oct. 31, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
One More Down Day and S&P 500 Ties 50-Year Record The S&P 500 (NYSEARCA:SPY) has been down 16 days in the month of October. If it closes down today, that will make 17, the most down days in a single month since 1970. While futures are up significantly this morning, there have been large reversals […] The post Market Morning: Record Down Days, Biotech Buyback Busts, Coke Raising Prices, Credit Tightens appeared first on Market Exclusive.